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Antisense oligonucleotide-mediated exon skipping is able to correct
out-of-frame mutations in Duchenne muscular dystrophy and restore
truncated yet functional dystrophins. However, its application is
limited by low potency and inefficiency in systemic delivery, espe-
cially failure to restore dystrophin in heart. Here, we conjugate a
phosphorodiamidate morpholino oligomer with a designed cell-
penetrating peptide (PPMO) targeting a mutated dystrophin exon.
Systemic delivery of the novel PPMO restores dystrophin to almost
normal levels in the cardiac and skeletal muscles in dystrophic mdx
mouse. This leads to increase in muscle strength and prevents cardiac
pump failure induced by dobutamine stress in vivo. Muscle pathology
and function continue to improve during the 12-week course of
biweekly treatment, with significant reduction in levels of serum
creatine kinase. The high degree of potency of the oligomer in
targeting all muscles and the lack of detectable toxicity and immune
response support the feasibility of testing the novel oligomer in
treating Duchenne muscular dystrophy patients.
Mutations in the dystrophin gene underlie two forms ofmuscular dystrophy: Duchenne and Becker muscular dys-
trophy (DMD and BMD). DMD is caused mainly by nonsense
and frame-shift mutations with little or no production of func-
tional dystrophin protein, leading to disease onset in early
childhood with lethal consequences. BMD is caused by muta-
tions that typically create shortened but in-frame transcripts with
production of partially functional dystrophin, leading to variable
and often overt symptoms (1–3). Most DMD mutations occur
within the rod domain, which spans more than half the length of
the protein, but seems to have limited functional importance (4,
5). Antisense therapy uses specific oligomers to remove the
mutated or additional exon(s) that disrupt the reading frame,
thus restoring the expression of shortened forms of dystrophin
protein retaining critical functions (6–11).
We previously demonstrated that i.m. delivery of a specific
2-O-methyl phosphorothioate antisense oligonucleotide
(2OMeAON) was able to skip targeted dystrophin exon 23 in mdx
mouse, a model of DMD (9). This mouse carries a nonsense point
mutation within exon 23 and lacks dystrophin expression (except in
a few rare revertant fibers) in all muscles, including the heart (12,
13). Skipping the mutated exon 23 restored both the reading frame
and dystrophin expression, with functional improvement of the
treated muscles (14) [supporting information (SI) Fig. S1a]. Re-
cently we showed that a phosphorodiamidate morpholino oligomer
(PMO), E237-18 targeting the junction of exon 23 and intron 23
of mouse dystrophin (referred to as PMOE23 hereafter), was able
to induce up to functional levels of dystrophin expression in some
skeletal muscles by regular i.v. injections in mdx mice (15). How-
ever, dystrophin expression induced by both 2OMeAON and PMO
required high doses and was highly variable between muscles and
myofibers in terms of observed efficacy. Of greater concern, cardiac
muscle seemed to be refractory to the antisense therapy, failing to
produce detectable dystrophin even after repeated treatment
(seven times at 60 mg/kg PMO per injection) (15). Both potency
and cardiac delivery represent major limitations to antisense ther-
apy as an effective treatment for DMD patients. Because DMD
patients live longer owing to improved multidisciplinary patient
care, rescuing dystrophin expression in cardiac muscle becomes
more critical for their longevity and quality of life (16–22). More
importantly, restoration of dystrophin only in skeletal muscles may
exacerbate the failure of heart function if dystrophin expression
cannot be effectively restored in cardiac muscle (18). It is not
understood why AON does not induce dystrophin expression
effectively in cardiac muscle, but low delivery efficiency seems to be
the most important contributing factor (15). Here we design and
examine a cell-penetrating peptide-tagged phosphorodiamidate
morpholino oligomer (PPMO) and demonstrate the restoration of
almost normal levels of dystrophin in cardiac and other types of
muscles bodywide in dystrophic mdx mice, with improvement in
muscle strength and cardiac function. The latter prevents heart
failure under increased workload conditions induced by dobut-
amine. Repeated treatment maintains levels of dystrophin and
ameliorates pathology, with significant reduction in levels of serum
creatine kinase without immune response.
Results
PPMO Induces Higher Efficiency of Exon Skipping than PMO. To
improve the efficiency of exon skipping in muscles, particularly
in cardiac muscle, we designed and examined the effect of several
arginine-rich cell-penetrating peptides linked to the same
PMOE23. The PMOE23 conjugated with the peptide of the
(RXRRBR)2XB sequence (R  arginine, X  6-aminohexanoic
acid, and B   alanine) (referred as PPMOE23 hereafter)
showed the highest efficiency for skipping exon 23 by i.m.
injection in the adult (age 4–5 weeks) mdx mouse (Fig. 1A).
Strong dystrophin expression was induced in 85% of the fibers
in the entire tibialis anterior (TA) muscle after injection of 2 g
of PPMOE23 (Fig. S1). The same amount of unmodified
PMOE23 produced only 14% dystrophin-positive fibers. A se-
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quence-scrambled PPMO (with the oligomer sequence not
complementary to the dystrophin gene but the same base
composition as PPMOE23) showed no effect on dystrophin
production. Specific skipping of exon 23 was confirmed by
RT-PCR and subsequent sequencing (data not shown). No
increases in muscle damage, inflammatory cellular infiltrates, or
necrotic fibers were observed microscopically in the muscles
injected with any of the PPMOs and PMO (data not shown).
Single-Dose PPMO Restores Near-Normal Levels of Dystrophin in
Skeletal Muscles. Therapeutic value of the antisense therapy to
DMD patients relies on systemic treatment. We therefore injected
a single dose of only 30 mg/kg of PPMO i.v. into adult mdx mice.
Administration of this amount of unmodified PMOE23 induced
dystrophin expression only in 5% or less of muscle fibers of all
skeletal muscles and no detectable dystrophin in cardiac muscle
when examined 2 weeks after injection (data not shown) (15). In
striking contrast, treatment with PPMOE23 produced strong dys-
trophin expression in 100% of fibers of all skeletal muscles exam-
ined, including the TA, quadriceps, gastrocnemius, abdominal,
intercostals, diaphragm, and biceps (Fig. 1 B–D). Expression of
dystrophin was highly homogeneous throughout the entire length of
the muscles (from tendon to tendon). In fact, the levels of dystro-
phin expression in the muscles of the PPMOE23-treated mice were
difficult to distinguish from that in the muscles of normal C57BL
mice by immunohistochemical analysis (Fig. 1 B–D). However,
variation in fiber size and specifically the presence of central
nucleation in most muscle fibers were the unmistakable remaining
pathology of the mdx mouse. Consistently, near-normal levels
(91–100%) of dystrophin were detected by Western blot (Fig. 1E).
The size of the PPMOE23-induced dystrophin was indistinguish-
able from that of the normal dystrophin. Similarly, dystrophin
mRNA with exon 23 skipped accounted for 80–86% of RT-PCR
products in all skeletal muscles (Fig. 1G). No off-target skipping of
the neighboring exons was observed (Fig. 1G). Precise skipping
of exon 23 was confirmed by sequencing (Fig. 1H). Restoration of
dystrophin expression also restored the  dystroglycan,  sarcogly-
can, and  sarcoglycan on fiber membrane (Fig. S2). Dystrophin
expression was not observed in the muscles of the mdx mice treated
with scrambled PPMO (Fig. 1 B–G).
Rescue of Dystrophin Expression in Cardiac Muscle. Importantly,
immunohistochemistry demonstrated membrane-localized dys-
trophin in 94% of cardiac muscle fibers of mdx mice treated with
the single dose of PPMOE23, although the levels of dystrophin
varied (Fig. 1D). Dystrophin was expressed at near-normal levels
in most areas of the cardiac muscle except in myofibers near the
ventricles and papillary muscles (Fig. S3 a and e). A 58% normal
dystrophin level was demonstrated by Western blot (Fig. 1E).
Consistently, dystrophin mRNA with exon 23 skipped accounted
for 63% of the dystrophin transcript by RT-PCR (Fig. 1G).
Expression of dystrophin also restored the membrane localiza-
tion of  dystroglycan and sarcoglycans (data not shown).
Regular PPMO Treatment Enhances Dystrophin Expression in Skeletal
and Cardiac Muscles. To assess whether regular injections of the
arginine-rich peptide can maintain or further enhance dystrophin
expression, a group of five adult mdx mice received 3-month
treatment with repeated (six times) i.v. injections of 30 mg/kg of
PPMOE23 at biweekly intervals. Two weeks after the last injection,
dystrophin expression remained in 100% of muscle fibers in all






Fig. 1. Structures of PMO and PPMO (A) and restora-
tion of dystrophin in muscles of mdx mice (aged 4–5
weeks) after a single i.v. injection of 30 mg/kg of
PPMOE23. The muscles were examined 2 weeks after
injection. (B–D) Detection of dystrophin by immuno-
histochemistry with rabbit polyclonal antibody P7
against dystrophin. Blue nuclear staining with DAPI.
(Scale bar, 100 M.) Muscles from normal C57BL mice
(B), scrambled PPMO-treated mdx mice (C), and PP-
MOE23-treated mdx mice (D). Dystrophin was homog-
enously expressed in all muscle fibers from the PP-
MOE23-treated mice. (E) Western blot demonstrated
dystrophin in all muscles detected with the NCL-DYS1
monoclonal antibody. C57-TA, tibialis anterior muscle
from normal C57BL; Gastro, gastrocnemius; Control-
TA, muscle from the scrambled PPMO-treated mdx
mouse. (F) Western blot for -actin as protein loading
control. (G) Detection of exon 23-skipped dystrophin
mRNA by RT-PCR. The upper 1,093-bp bands (indicated
by E22-E23-E24) correspond to the normal mRNA, and
the lower 880-bp bands (indicated by E22-E24) corre-
spond to the mRNA with exon 23 skipped. Sequencing
of the 880-bp RT-PCR product confirmed the skipping
of the exon 23 (H).

















the small intestine (Figs. 2 A–C and 3). The levels of dystrophin
expression detected by both immunohistochemistry and Western
blot in the PPMOE23-treated mdx mice were again indistinguish-
able from those in normal C57BL mouse (Fig. 2D). The dystrophin
mRNA with exon 23 skipped accounted for nearly 90% (85–92%)
of total dystrophin mRNA by RT-PCR in all skeletal muscles
(Fig. 2F).
Most significantly, repeated injections of PPMOE23 further
enhanced specific exon skipping and dystrophin expression in the
cardiac muscle. The dystrophin mRNA with exon 23 skipping
increased to 72% of normal levels (Fig. 2F). Immunohistochem-
istry and Western blot revealed dystrophin expression through-
out the whole heart muscle, with levels comparable to that in
normal heart (Figs. 2D and 4 A–C, and Fig. S3b). Furthermore,
strong and homogeneous dystrophin expression was also
achieved in the muscles of the atria and in the smooth muscle of
large vessels, including the aorta, vena cava, and the pulmonary
arteries (Fig. 3 F and G).
Dystrophin Expression Improves Pathology of Skeletal Muscles. Res-
toration of near-normal levels of dystrophin in all skeletal muscles
after PPMOE23 treatment unambiguously improved pathology in
the treated mice. Improvement in cell membrane permeability was
observed with Evan’s blue dye and staining for Igs (19, 20). Two
weeks after a single 30-mg/kg i.v. injection, the number of dye-
stained and Ig-positive fibers was significantly reduced in
PPMOE23-treated muscles compared with muscles in the un-





Fig. 2. Restoration of dystrophin in bodywide mus-
cles of mdx mice (age 4–5 weeks) after six i.v. injections
of 30 mg/kg of PPMOE23 at biweekly intervals. Muscles
were examined 2 weeks after the last injection. Muscles
from normal C57BL mice (A), scrambled PPMO-treated
mdx mice (B), and PPMOE23-treated mdx mice (C). Blue
nuclear staining with DAPI. Dystrophin was expressed
homogenously in all muscle fibers from the PPMOE23-
treated mdx mice. (Scale bar, 100 m.) (D) Western blot
demonstrated near-normal levels of dystrophin in all
muscles detected with the NCL-DYS1 monoclonal anti-
body. C57-TA, TA muscle from normal C57BL mouse;
Control-TA, TA muscle from scrambled PPMO-treated
mdx mouse; Gastro, gastrocnemius. (E) Western blot
for -actin as protein loading control. (F) Detection of
exon 23 skipping by RT-PCR. Total RNA of 100 ng from
each sample was used for amplification of dystrophin
mRNA from exon 20 to exon 26. Control-TA, TA muscle
from scrambled PPMO-treated mdx mouse. The upper
1,093-bp bands (indicated by E22-E23-E24) correspond
to the normal dystrophin mRNA, and the lower 880-bp
bands (indicated by E22-E24) correspond to the mRNA





Fig. 3. Restoration of dystrophin in skeletal and smooth muscles after six
cycles of 30-mg/kg PPMOE23 injection. Back thoracic and lumbar muscle (A),
digital muscle (B), flexor muscle (C). Smooth muscles (layers between the two
arrows) in small intestine of untreated mdx mouse (D) and PPMOE23-treated
mdx mouse (E). Arrowhead indicates a revertant fiber. Dystrophin expression
in the smooth muscle of aorta and vena cava (F) and arteries and other vessels
in the lung (G). Dystrophin was detected by immunostaining with rabbit
polyclonal antibody P7. Blue nuclear staining with DAPI. (Scale bars: A–E, 50
m; F and G, 120 m.)
A B C
Fig. 4. Dystrophin expression in cardiac muscle after PPMOE23 treatment (30
mg/kg six times at biweekly intervals). Muscles from normal C57BL mouse (A),
PPMOE23-treated mdx mouse (B), and scrambled PPMO-treated mdx mouse
(C). The muscles were examined 2 weeks after last injection of PPMOs. Dys-
trophin was detected by immunohistochemistry with rabbit antibody P7 and
visualized by Alexa 594 conjugated goat antirabbit Igs. Blue nuclear staining
with DAPI. (Scale bar: 100 m.)
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(one or two) muscle fibers were stained positive with the dye and
for Igs in all of the muscles of the mice treated with PPMOE23,
whereas 20 or more positive fibers, often in groups, were observed
in each muscle of the untreated and scrambled PPMO-treated mdx
mice (Fig. S4 a and b). The amount of Ig in the extracellular matrix
was also considerably reduced in the muscles of the mdx mice
treated with PPMOE23, indicating an improved integrity of the
vasculature bed. The improved muscle pathology was strongly
supported by a significant reduction in serum levels of creatine
kinase in PPMOE23-treated mice (Fig. S4c).
The most significant improvement in pathology was seen after 3
months’ regular treatment with PPMO. First, muscle fibers dis-
played more healthy polygonal shapes and became highly uniform.
Fibers of small caliber, a sign of previous regeneration, became rare
in all muscles (Fig. 5 A–C and F). This contrasted sharply with
muscles of both the untreated and scrambled PPMO-treated mdx
mice, in which fiber size varied significantly and groups of regen-
erating fibers were evident. No foci of mononucleate infiltrates were
observed in any muscles of the PPMOE23-treated mice (Fig. 5C).
Second, the number of centrally nucleated fibers was significantly
reduced in all muscles of mdx mice treated with PPMOE23,
indicating decreased degeneration and regeneration (Fig. 5D). The
improvement in muscle pathology was most conspicuous in the
diaphragm. Untreated and scrambled PPMO-treated mdx mice had
prominent degeneration and regeneration, indicated by large vari-
ation in fiber size, widespread foci of newly regenerated fibers, and
mononucleate infiltrates in the extracellular matrix (Fig. 5 B and F).
Degenerating fibers with a rounded shape and condensed cyto-
plasm were abundant (Fig. 5B). However, PPMOE23 treatment
improved homogeneity of fiber size and diminished mononucleate
infiltrates (Fig. 5 C and F).
Restitution of Skeletal Muscle Function. We evaluated skeletal mus-
cle function with a battery of tests. The forelimb maximum grip
force showed substantial improvement in PPMOE23-treated adult
mdx mice as early as 2 weeks after two cycles of i.v. injection (Fig.
S5a). The group of mdx mice receiving 3 months of biweekly
treatment with PPMOE23 continued to show improvement in the
maximum grip forces of both forelimbs and hindlimbs (Fig. 5E), as
well as improvement in endurance by rotarod tests (Fig. S5b). The
muscle functional improvement was supported by significant re-
duction in serum creatine kinase levels (Fig. 5G).
Improvement in Cardiac Function Prevents Heart Failure. Next, we
examined whether PPMOE23 treatment could also improve the
cardiac function of mdx mice. Consistent with previous reports,
microscopic examination and ultrahigh-frequency echocardiog-
raphy of the PPMOE23-treated mdx mice showed normal his-
tology and ventricular function of the heart (Fig. S5c). However,
heart dysfunction of mdx mice can be demonstrated by hemo-
dynamic analysis under dobutamine stress (21–25). We therefore
examined 4-month-old male mdx mice 3 weeks after two
PPMOE23 treatments (30 mg/kg at biweekly intervals) along
with age- and sex-matched untreated mdx and healthy C57BL
control mice. A -adrenergic stimulant, dobutamine, was used to
increase cardiac workload and further magnify the dysfunctions
in mdx heart (23–25). Under baseline conditions, the untreated
mdx heart showed minor deficits, especially in stroke volume,
cardiac output, end-systolic pressure, maximal rate of isovolumic
contraction (dp/dtmax), and maximal rate of isovolumic relax-
ation (dp/dtmin) when compared with C57BL control mice.
Expression of dystrophin after PPMOE23 treatment improved
dp/dtmax, dp/dtmin, and end-systolic pressure (Table S1).
After dobutamine infusion, however, mdx mice revealed signif-
icant cardiac dysfunction, with progressive decline in end-diastolic
volume, end-systolic pressure, and dp/dtmax and an increase in
dp/dtmin (Fig. 6 A–E and Table S2). There was a marked leftward
shift of cardiac pressure/volume loops after dobutamine challenge
(Fig. 6 G and H), and 60% of the mdx mice did not survive the
30-min procedure (Fig. 6F). Conversely, the PPMOE23-treated
mdx mice showed much-improved cardiac function, especially in
end-systolic pressure, dp/dtmax, dp/dtmin, and end-diastolic volume,
and lack of left-shift of the pressure/volume loop, similar to healthy
control C57BL mice (Fig. 6 A–E, G, and H and Table S2). Like
C57BL, all treated mdx mice survived the dobutamine challenge
(Fig. 6F). Finally, near-normal levels of dystrophin expression in the
heart of PPMO-treated mdx mice were confirmed by immunohis-
tochemical staining (Fig. 6 I and J) and Western blot (data not
shown) after hemodynamic analysis. These results indicate that





Fig. 5. Histology of mouse muscles (hematoxylin eosin staining) from the
normalC57BLmice(A), scrambledPPMO-treatedmdxmice(B),PPMOE23-treated
(six times) mdx mice (C), and percentage of centrally nucleated fibers (CNF) (D) in
the skeletal muscles of the mdx mice treated with PPMOE23 and scrambled (SCR)
PPMO. Gastro, gastrocnemius. (Scale bar: 100 m.) Significant difference was
observedbetweenthetwogroups (n5;*,P  0.05, two-tailed t test). (E) Testing
of muscle function. Significant improvement was observed for both maximum
forelimb and hindlimb strength in mdx mice treated with PPMOE23 when com-
pared with mdx mice treated with scrambled PPMO (n  5; *, P  0.05, two-tailed
t test), and no significant differences were observed between mdx mice treated
withPPMOE23andnormalC57BLmice.KGF,kilogramforce. (F)Numberofnewly
regenerating fibers (20 m in diameter) in muscles of mdx mice after six cycles
of PPMOE23 treatment in comparison with scrambled (SCR) PPMO-treated mdx
mice. Gastro, gastrocnemius. A total of 1,000 fibers were assessed for each muscle
sample (n  5; *, P  0.05, two-tailed t test). (G) Serum testing. CK, creatine kinase
(KU/liter), creatinine (mg/liter), urea nitrogen (mg/ml), total bilirubin (mg/liter),
direct bilirubin (mg/dl), ALT (unit/dl), alkaline phosphatase (U/dl), and Gamma-
glutamyltransferase (GGT) (unit/liter). A significant reduction in creatine kinase
levels was observed in PPMOE23-treated mdx mice compared with scrambled
PPMO-treated mdx mice (n  5; *, P  0.05, two-tailed t test).

















diac function of dystrophic heart and prevent acute cardiac decom-
pensation under increased workload conditions.
Lack of Detectable Toxicity and Immune Response. Histologic ex-
amination revealed no pathologic changes in liver and kidney of
mdx mice after both single and repeated PPMO treatment(s)
(Fig. S6). This was consistent with the serum testing results
showing that levels of alkaline phosphatase and creatinine were
unchanged compared with control mdx mice (Fig. 5G).
We also looked for potential immune response to the PPMOs
delivered either locally or systemically. No accumulation of inflam-
matory cells, including microphages, was detected in any muscles.
Consistently, only a few sporadically distributed T lymphocytes
were observed by immunohistochemistry in all muscles after
PPMOE23 treatment (Fig. S6 b and c). Specific humoral immune
responses were also examined by ELISA to detect antibodies
against PPMO. Serum from mice after single and repeated admin-
istration of PPMO showed only background signals similar to serum
from normal C57BL and untreated mdx mice (Fig. S6d).
Discussion
One major concern that arises with the use of peptides as delivery
enhancers is the immune response they might elicit, preventing
repeated administration and causing rejection of targeted tissues.
This is particularly important given that long-term, repeated ad-
ministrations are required for the treatment of DMD with antisense
therapy. However, we observed no signs of immune response to the
PPMOs delivered either locally or systemically. Humoral immune
response to the PPMO was also undetectable after repeated PPMO
administration. The most compelling evidence was the sustained
near-normal levels of dystrophin expression in skeletal muscles and
enhanced dystrophin expression in cardiac muscle, with improved
muscle pathology and function after 3 months of treatment. This is
consistent with previous reports showing lack of immunogenicity
with similar peptides in animal models (26, 27). The use of
unnatural amino acids in the peptide sequence of the PPMO most
likely contributes to the lack of immunogenicity. However, only
short-term use of arginine-rich peptide has been reported in human
clinical trials (28). The principle of precaution together with the fact
that immunogenicity varies considerably between species would
argue for longer-term studies in other species. Nevertheless, the
known sequence and structure of our peptide provide bases for
modeling to develop possible nonpeptide polymers with similar or
even improved function as effective delivery vehicles.
Strategies of gene and protein replacement therapy for DMD,
such as gene and cell therapies as well as antisense therapy, have
met the challenge to achieve homogenous protein expression
throughout the bodywide musculature (5, 14, 29). Effort has
been made to improve antisense effect by modification of AONs
with cell-penetrating peptides, but with limited success (30, 31).
Fletcher et al. (31) used a PMO tagged with an arginine-rich
peptide for exon 23 skipping in mdx mice and reported resto-
ration of near-normal levels of dystrophin in diaphragm by i.p.
injections. However, only 8% normal levels of dystrophin were
produced in all other skeletal and cardiac muscles. The failure to
restore dystrophin in cardiac muscle could severely reduce the
clinical value of antisense therapy. Of greater concern is that
restoration of dystrophin in skeletal muscles but not in cardiac
muscle could exacerbate the existing heart dysfunction as a result
of increased workload with the improvement of skeletal muscle
function (18). Here we show that PPMO as antisense oligonucle-
otide chemistry can achieve almost full restoration of dystrophin in
cardiac and all skeletal muscles. This achievement has several
important implications. First, these results prove the principle that
cardiac muscles can be effectively targeted for specific exon skip-
ping and rescue of dystrophin expression (32–34). Second, the AON
used in our study has been screened and selected using skeletal
muscle myoblasts as targets. High-efficiency exon skipping in all
types of muscles (cardiac, skeletal, and smooth muscle) in vivo after
the same AON treatment suggests that skeletal myoblast cultures
may be a reliable system for patient-specific AON selections. This
is particularly important for antisense therapies targeting specific
exons of human dystrophin for clinical trials, because only skeletal
myoblasts but not cardiomyocytes are available from patients.
Third, the finding that PPMOE23 could also effectively enter and
correct smooth muscle cells in the vasculature and the digestive
system is striking and remains to be further investigated. It has been
documented that dystrophin deficiency in blood vessel smooth
muscles caused deficits in circulation and could be corrected after
dystrophin restoration (35). Finally, effective targeting of cardiac






Fig. 6. Improvement of cardiac hemodynamic function and survival of
PPMOE23-treated (two 30-mg/kg i.v. injections, examined 3 weeks after the last
injection) mdx mice (aged 4 months) at 15 min after dobutamine challenges.
Significant improvement was observed in end-systolic pressure (A), dp/dtmax (B),
dp/dtmin (C), and end-diastolic volume (D). (E) End-systolic volume. (F) Percentage
survival of untreated mice (red), PPMOE23-treated mdx mice (green), and C57BL
mice (blue) within 30 min after dobutamine challenges. (G) Representative
pressure/volume loops in paired mice before dobutamine treatment (baseline).
(H) The loop shifts dramatically leftward and downward in the untreated mdx
heart (red) but stabilized in the PPMOE23-treated mdx heart (green), similar to
the loop in C57BL heart (blue) at 15 min after dobutamine treatment. RVU,
relative volume units. (I) Heart from untreated mdx mouse and (J) heart from
PPMOE23-treated mdx mouse after hemodynamic analysis and stained for dys-
trophin expression. One hundred percent of cardiac muscle fibers express dys-
trophin(J).BluenuclearstainingwithDAPI.C57BL,n10;PPMOE23-treatedmdx
mice, n  8; untreated mdx mice, n  9. *, P  0.05, t test.
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dysfunction provides the possibility for rescue of cardiac muscle in
DMD patients. Furthermore, almost 100% efficiency in targeting
gene transcripts systemically in a disease model demonstrates the
power of oligonucleotide therapy, not only for DMD but also for
many other diseases, such as viral infections and cancers (36).
Materials and Methods
Animals, Oligonucleotides, and Delivery Methods. The mdx mice and C57 Black
10 (C57BL) aged 4–5 weeks and 4 months, respectively, were used in each group.
Experimentswereapprovedbythe InstitutionalAnimalCareandUseCommittee,
Carolinas Medical Center. The PMO M23D(07–18) (5-GGCCAAACCTCG GCT-
TACCTGAAAT-3) against the boundary sequences of exon and intron 23 of
dystrophin gene (PMOE23) and the scrambled oligomers (5-GCGCAAAC-
CTCGCGTTACCGTAAAT-3) as a control were used (AVI BioPharma). The PMO
wasconjugatedtothepeptide (RXRRBR)2XBthroughanoncleavageamide linker
(37) to form a peptide-PMO conjugate (PPMO). For i.m. injections, 2 g of PMO
or PPMO were used in saline for each TA muscle. For i.v. administration, 30 mg/kg
of PMO or PPMO was used in 100 l of saline by retro-orbital injections.
Antibodies and Immunohistochemistry. Serial sections were stained with a panel
of polyclonal and monoclonal antibodies for the detection of dystrophin and
dystrophin-associated proteins, as described (9, 38). Tissue endogenous Igs were
detected with rabbit antimouse Igs Alexa 488 (Invitrogen). FITC-labeled mono-
clonal antibody against mouse CD3 was obtained from EBioscience.
Protein Extraction and Western Blot. Protein extraction and Western blot were
done as described (39). The membrane was probed with monoclonal antibody
NCL-DYS1 against dystrophin rod domain (Vector Laboratories). The bound
primary antibody was detected by HRP-conjugated goat antimouse IgG. The
intensity of the bands obtained from the oligomer-treated mdx mice muscles was
measured and compared with that from normal muscles of C57BL mice (National
Institutes of Health imaging software, gel blotting macros). Alpha-actin was
detectedbyrabbitantiactinantibody(Sigma)andusedassample loadingcontrol.
RNA Extraction and RT-PCR. Total RNA was extracted, and 100 ng of RNA
template was used for a 50-l RT-PCR with the Stratascript One-Tube RT-PCR
System (Stratagene). The primer sequences for the RT-PCR were Ex20Fo 5-
CAGAATTCTGCCAATTGCTGAG-3 and Ex26Ro 5-TTCTTCAGCTTGTGTCATCC-3
for amplification of mRNA from exons 20–26. Bands with the expected size for
the transcript with exon 23 deleted were extracted and sequenced. The intensity
of the bands representing mRNAs with and without exon 23 skipping was
measured (added together as 100%) by National Institutes of Health imaging
software (gel blotting macros), and relative percentage of the mRNA with exon
23 skipping was calculated.
Grip Strength Test. Grip strength was assessed with a grip strength meter
consisting of horizontal forelimb mesh and an angled hindlimb mesh (Columbus
Instruments). Five successful hindlimb and forelimb strength measurements
within2minwererecorded.Themaximumvaluesofeachdayovera5-dayperiod
were used for subsequent analysis. The grip strength measurements were col-
lected in the morning hours over a 5-day period, and data were normalized to
body weight and expressed as kilogram force.
In Vivo Cardiac Hemodynamics. Hemodynamic analysis on the treated and
untreated mdx mice as well as the C57BL mice (aged 4 months) were performed
using conductance micromanometry according to previously published methods
(23–25). Briefly, the mice were anesthetized by inhalation of 1% isoflurane and
99% oxygen. The mice were then ventilated at 120 strokes per minute with a
rodent ventilator (Harvard Instruments) and kept on a warm pad to stabilize the
body temperature at 37°C. After thoracotomy and pericardiotomy, a 1.4-F high-
fidelity micromanometer catheter (Millar Instruments) was inserted into the left
ventricle under continuous hemodynamic monitoring. After collection of base-
line hemodynamic data, dobutamine was infused at a rate of 20 ng/g per min for
3 min through the jugular vein. Pressure/volume loop data were collected online
at 500 Hz. Hemodynamic parameters were analyzed with PVAN3.3 software
(Millar Instruments).
ACKNOWLEDGMENTS. We thank Dr. Herbert Bonkovsky, Cannon Research
Center, Carolinas Medical Center, and Dr. Eric Hoffman, Children’s National
Medical Center, for critical comments on the manuscript. This work was
supported by the Carolinas Muscular Dystrophy Research Endowment at the
Carolinas HealthCare Foundation and Carolinas Medical Center; Muscular
Dystrophy Association; and United States Army Medical Research, Depart-
ment of Defense (W81XWH-05–1-0616).
1. Hoffman EP, Brown RH, Jr, Kunkel LM (1987) Dystrophin: The protein product of the
Duchenne muscular dystrophy locus. Cell 51;919–928.
2. Laing NG (1993) in Molecular Cell Biology of Muscular Dystrophy, ed Partridge TA
(Chapman, London), pp 37–77.
3. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988) An explanation
for the phenotypic differences between patients bearing partial deletions of the DMD
locus. Genomics 2:90–95.
4. England SB, et al. (1990) Very mild muscular dystrophy associated with the deletion of
46% of dystrophin. Nature 343:180–182.
5. Gregorevic P, et al. (2004) Systemic delivery of genes to striated muscles using adeno-
associated viral vectors. Nat Med 10:828–834.
6. Sherratt TG, Vulliamy T, Dubowitz V, Sewry CA, Strong PN (1993) Exon skipping and
translation in patients with frameshift deletions in the dystrophin gene. Am J Hum
Genet 53:1007–1015.
7. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G (1998) Modification of
splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonu-
cleotides. Hum Mol Genet 7:1083–1090.
8. Mann CJ, et al. (2001) Antisense-induced exon skipping and synthesis of dystrophin in
the mdx mouse. Proc Natl Acad Sci USA 98:42–47.
9. Lu QL, et al. (2003) Functional amounts of dystrophin produced by skipping the
mutated exon in the mdx dystrophic mouse. Nat Med 9:1009–1014.
10. Dickson G, Hill V, Graham IR (2002) Screening for antisense modulation of dystrophin
pre-mRNA splicing. Neuromuscul Disord 12(Suppl 1):S67–S70.
11. Aartsma-Rus A, et al. (2002) Targeted exon skipping as a potential gene correction
therapy for Duchenne muscular dystrophy. Neuromuscul Disord 12(Suppl 1):S71–S77.
12. Lu QL, et al. (2000) Massive idiosyncratic exon skipping corrects the nonsense mutation
in dystrophic mouse muscle and produces functional revertant fibers by clonal expan-
sion. J Cell Biol 148:985–996.
13. Wilton SD, Dye DE, Blechynden LM, Laing NG (1997) Revertant fibres: A possible
genetic therapy for Duchenne muscular dystrophy? Neuromuscul Disord 7:329–335.
14. Goyenvalle A, et al. (2004) Rescue of dystrophic muscle through U7 snRNA-mediated
exon skipping. Science 306:1796–1799.
15. Alter J, et al. (2006) Systemic delivery of morpholino oligonucleotide restores dystro-
phin expression bodywide and improves dystrophic pathology. Nat Med 12:175–177.
16. Foster K, Foster H, Dickson JG (2006) Gene therapy progress and prospects: Duchenne
muscular dystrophy. Gene Ther 13:1677–1685.
17. Wagner KR, Lechtzin N, Judge DP (2007) Current treatment of adult Duchenne mus-
cular dystrophy. Biochim Biophys Acta 1772:229–237.
18. Townsend D, Yasuda S, Li S, Chamberlain JS, Metzger JM (2008) Emergent dilated cardio-
myopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 16:832–835.
19. Matsuda R, Nishikawa A, Tanaka H (1995) Visualization of dystrophic muscle fibers in
mdx mouse by vital staining with Evans blue: Evidence of apoptosis in dystrophin-
deficient muscle. J Biochem (Tokyo) 118:959–964.
20. Silver MM, Banerjee D, Hudson AJ (1983) Segmental myofiber necrosis in myotonic
dystrophy: An immunoperoxidase study of immunoglobulins in skeletal muscle. Am J
Pathol 112:294–301.
21. Bostick B, Yue Y, Long C, Duan D (2008) Prevention of dystrophin-deficient cardiomy-
opathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or
complementary dystrophin/utrophin expression. Circ Res 102:121–130.
22. Quinlan JG, et al. (2004) Evolution of the mdx mouse cardiomyopathy: Physiological
and morphological findings. Neuromuscul Disord 14:491–496.
23. Burger AJ, Notarianni MP, Aronson D (2000) Safety and efficacy of an accelerated
dobutamine stress echocardiography protocol in the evaluation of coronary artery
disease. Am J Cardiol 86:825–829.
24. Townsend D, et al. (2007) Systemic administration of micro-dystrophin restores cardiac
geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 15:1086–
1092.
25. Yasuda S, et al. (2005) Dystrophic heart failure blocked by membrane sealant polox-
amer. Nature 436:1025–1029.
26. Toro A, Grunebaum E (2006) TAT-mediated intracellular delivery of purine nucleoside
phosphorylase corrects its deficiency in mice. J Clin Invest 116:2717–2726.
27. Lupfer C, et al. (2008) Inhibition of influenza A H3N8 virus infections in mice by
morpholino oligomers. Arch Virol 153:929–937.
28. Bates E, et al. (2008) Intracoronary KAI-9803 as an adjunct to primary percutaneous
coronary intervention for acute ST-segment elevation myocardial infarction. Circula-
tion 117:886–896.
29. Price FD, Kuroda K, Rudnicki MA (2007) Stem cell based therapies to treat muscular
dystrophy. Biochim Biophys Acta 1772:272–283.
30. Yin H, Lu QL, Wood M (2008) Effective exon skipping and restoration of dystrophin
expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther
16:38–45.
31. Fletcher S, et al. (2007) Morpholino oligomer-mediated exon skipping averts the onset
of dystrophic pathology in the mdx mouse. Mol Ther 15:1587–1592.
32. Abes S, et al. (2006) Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide
allows efficient splicing correction in the absence of endosomolytic agents. J Control
Release 116:304–313.
33. Kurreck J (2003) Antisense technologies. Improvement through novel chemical mod-
ifications. Eur J Biochem 270:1628–1644.
34. Summerton J, Weller D (1997) Morpholino antisense oligomers: Design, preparation,
and properties. Antisense Nucleic Acid Drug Dev 7:187–195.
35. Ito K, et al. (2006) Smooth muscle-specific dystrophin expression improves aberrant
vasoregulation in mdx mice. Hum Mol Genet 15:2266–2275.
36. Blow N (2007) Small RNAs: Delivering the future. Nature 450:1117–1120.
37. Wu RP, et al. (2007) Cell-penetrating peptides as transporters for morpholino oli-
gomers: Effects of amino acid composition on intracellular delivery and cytotoxicity.
Nucleic Acids Res 35:5182–5191.
38. Lu QL, Partridge TA (1998) A new blocking method for application of murine mono-
clonal antibody to mouse tissue sections. J Histochem Cytochem 46:977–984.
39. Lu QL, et al. (2005) Systemic delivery of antisense oligoribonucleotide restores dystro-
phin expression in bodywide skeletal muscles. Proc Natl Acad Sci USA 102:198–203.
Wu et al. PNAS  September 30, 2008  vol. 105  no. 39  14819
A
PP
LI
ED
BI
O
LO
G
IC
A
L
SC
IE
N
CE
S
